This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Enumeral Biomedical Holdings, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Thomas Mcquade: Innovator in Antibody Development
Introduction
Thomas Mcquade is a notable inventor based in the United States. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work focuses on innovative solutions that have the potential to impact medical treatments.
Latest Patents
Although Thomas Mcquade currently holds 1 patents, his research has led to the development of groundbreaking concepts. One of his notable inventions is related to Anti-PD-1 Antibodies. These antibodies bind to programmed cell death protein 1 (PD-1), which plays a crucial role in regulating immune responses. The compositions comprising such antibodies, along with methods of making and using them, are essential for advancing therapeutic strategies.
Career Highlights
Throughout his career, Thomas Mcquade has focused on the intersection of immunology and therapeutic development. His innovative approach to antibody design has garnered attention in the scientific community. He has dedicated his efforts to exploring new avenues for enhancing immune responses against various diseases.
Collaborations
Thomas Mcquade has worked alongside esteemed colleagues, including Hareesh Chamarthi and Daniel Doty. Their collaborative efforts have contributed to the advancement of antibody research and development.
Conclusion
In summary, Thomas Mcquade is an influential figure in the field of antibody development, with a focus on Anti-PD-1 Antibodies. His innovative work and collaborations highlight the importance of research in advancing medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile